Skip to main content
Signal8
Launch Terminal

Keros Therapeutics, Inc. (KROS)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

NASDAQ:KROSHealthcare
+0.65%$10.83
CLOSED
AH$10.83+0.00%vs close
Mkt Cap$214.73M
Float18.46M
O/S19.83M
VOL106K sh
$ Vol$1.16M
RVOL0.66×
Inst Own93.8%
SI6.2%
EarningsNov 4 · Today
Dilution
Keros Therapeutics, Inc. logoNASDAQ:KROSClosed$10.83+0.65%
Historical Data
DateOpenHighLowCloseVolume
Nov 3, 202610.7811.1110.7810.83106,334
Nov 2, 202611.1211.3910.5310.76139,245
Oct 30, 202611.3211.4910.9711.04120,160
Oct 29, 202611.7111.8811.2111.36205,119
Oct 28, 202611.3411.7911.2011.61183,224
Oct 27, 202611.3711.6311.1911.43148,511
Oct 26, 202611.3011.5111.2011.33112,410
Oct 23, 202611.2811.3410.9211.28120,902
Oct 22, 202611.1511.4411.1511.35115,512
Oct 21, 202611.4011.6811.1111.18178,141
Oct 20, 202611.0411.6611.0411.40153,379
Oct 19, 202610.6811.1510.6611.06210,647
Oct 16, 202611.1111.1310.6310.66169,639
Oct 15, 202611.1311.4010.9811.1096,666
Oct 14, 202611.0711.3010.9211.05159,137
Oct 13, 202611.6511.6911.1911.23144,293
Oct 12, 202611.7712.0811.5811.61223,679
Oct 9, 202611.5812.2611.4911.95194,393
Oct 8, 202611.1311.7610.9911.64245,658
Oct 7, 202610.8111.3410.8111.21195,963
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
10
HOLD
7
SELL
0
TOTAL17
Insider Trades
InsiderTypeShares
Newton Charles W. profile photoNewton Charles W.Sale551
Cho Esther profile photoCho EstherSale4.5K
Lerner Lorena Raquel profile photoLerner Lorena RaquelSale3.6K
Tanini Annita profile photoTanini AnnitaSale1.2K
BIENAIME JEAN JACQUES profile photoBIENAIME JEAN JACQUESPurchase1.0K
BIENAIME JEAN JACQUES profile photoBIENAIME JEAN JACQUESPurchase1.0K
Shareholders
93.8%
Institutional
(133)
4.0%
Insiderⓘ
(17)
9.1%
5%+ Owners
(1)
-
Unattributed (incl. retail)ⓘ
Institutional93.8%
Insider4.0%
5%+ Beneficial9.1%
Sources: 13F, Form 4, 13D/13GO/S: 19.8M · as of 27 Jul 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.

Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Key Metrics
Market Cap$214.73M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership93.83%

based on 19.83M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateApr 8, 2020
Shares Outstanding19.83M
Float18.46M
52-Week Range
$9.69$22.55
$10.83(9th percentile)
Volume
Average Daily Volume160.94K
106.33K today vs 160.94K avg(-34%)

30d Avg

160.94K

60d Avg

177.22K

90d Avg

183.51K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...